SYNAREL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SYNAREL (SYNAREL).
Synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH). Binds to pituitary GnRH receptors, initially stimulating then desensitizing them, leading to suppressed LH and FSH secretion, decreased gonadal steroid production (estrogen, testosterone).
| Metabolism | Metabolized by peptidases in plasma and tissues (no specific CYP enzyme involvement). |
| Excretion | Renal: ~90% as parent drug and metabolites; fecal: <10%. |
| Half-life | Terminal elimination half-life: ~3 hours (range 2-5 hours) after intranasal administration; clinically, dosing every 12 hours maintains therapeutic levels. |
| Protein binding | ~70% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd: ~1.1 L/kg (range 0.8-1.5 L/kg), indicating extensive distribution into total body water and tissues. |
| Bioavailability | Intranasal: ~5% (range 2-10%) relative to subcutaneous injection, due to limited nasal absorption and first-pass metabolism. |
| Onset of Action | Intranasal: suppression of gonadotropins within 2-4 hours; maximal suppression of LH and FSH occurs within 2-4 weeks of continuous therapy. |
| Duration of Action | Intranasal: serum levels decline below therapeutic threshold within 6-12 hours after a single dose; chronic therapy results in sustained pituitary desensitization lasting as long as treatment continues. |
| Molecular Weight | 1322.64 |
200 mcg intranasally twice daily (400 mcg total daily dose) for 6 months. Initiate on day 5 of menstural cycle.
| Dosage form | SPRAY, METERED |
| Renal impairment | No specific dose adjustment provided for GFR-based modifications. Use with caution in severe renal impairment. |
| Liver impairment | No specific dose adjustment provided for Child-Pugh-based modifications. |
| Pediatric use | Not indicated for use in pediatric patients. |
| Geriatric use | Not indicated for use in geriatric patients; no specific dose adjustment available. |
| 1st trimester | Contraindicated: risk of teratogenicity; may cause fetal harm based on animal studies and its mechanism of action as a GnRH agonist. |
| 2nd trimester | Contraindicated: continued risk of fetal harm; no adequate human studies; potential for pregnancy loss. |
| 3rd trimester | Contraindicated: risk of fetal harm, including potential for hormonal disruption; use only if clearly needed for maternal condition. |
Clinical note
Comprehensive clinical and safety monograph for SYNAREL (SYNAREL).
| Placental transfer | Likely crosses placenta due to small molecular weight and lipophilic nature; no specific human data but animal studies show fetal exposure. |
| Breastfeeding | Excretion into human milk unknown; due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to nafarelin or any component of formulationPregnancyUndiagnosed abnormal vaginal bleeding
| Precautions | Rapid symptom improvement does not rule out malignancy; evaluate if no response within 4 weeks., Bone mineral density loss with prolonged use; consider risk-benefit for conditions requiring >6 months therapy., Hypersensitivity reactions including anaphylaxis have been reported., May cause ovarian cyst enlargement in initial weeks; monitor with ultrasound if pelvic pain occurs., Cannot be used in children with precocious puberty until bone age confirmed. |
| Food/Dietary | No known food interactions. Take without regard to meals. |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | FDA Pregnancy Category X. Contraindicated in pregnancy. Risk of fetal harm, including congenital malformations (e.g., craniofacial, CNS, cardiovascular defects) and pregnancy loss, particularly during first trimester due to gonadotropin suppression and hormonal alterations. Avoid use in pregnant women. |
| Fetal Monitoring | Pregnancy test before initiating therapy; confirm non-pregnant status. Monitor for signs of pregnancy loss or fetal anomalies if exposure occurs. Ultrasonography for fetal assessment if inadvertent use during pregnancy. |
| Fertility Effects | Inhibits gonadotropin secretion, leading to suppressed ovulation and spermatogenesis, causing reversible infertility. Return to fertility typically after discontinuation. |
| Clinical Pearls |
| Synarel (nafarelin acetate) is a GnRH agonist used for central precocious puberty (CPP) and endometriosis. For CPP, monitor growth velocity and bone age advancement every 3-6 months. For endometriosis, duration of therapy is limited to 6 months due to risk of bone loss. Reassess bone density if retreatment is considered. Nasal administration may be affected by nasal congestion; instruct patients to clear nasal passages before use. Estradiol levels should drop to prepubertal range in CPP; failure suggests noncompliance or incorrect dosing. |
| Patient Advice | Use exactly as prescribed; do not miss doses. · Before each use, gently blow nose to clear nasal passages. · Prime the pump by actuating 2-3 sprays into the air if first use or not used for 7 days. · Alternate nostrils each dose; place the spray tip into nostril and depress pump firmly while breathing in gently. · Do not sniff forcefully after spraying to keep the medicine in the nose. · Store at room temperature, away from heat and light. · Report any signs of allergic reaction, persistent nasal irritation, or changes in menstruation. · For endometriosis, use contraception concurrently during first 2 months of therapy. · Notify healthcare provider if you become pregnant or plan to breastfeed. · May cause hot flashes, mood swings, and vaginal dryness; these are expected effects of estrogen suppression. |